Predicting the sites of metastases by Ring, Brian Z & Ross, Douglas T
Genome Biology 2005, 6:241
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
Minireview
Predicting the sites of metastases 
Brian Z Ring and Douglas T Ross
Address: Applied Genomics Inc., 525 Del Rey Avenue, Sunnyvale, CA 94085, USA. 
Correspondence: Brian Z Ring. E-mail: bzring@applied-genomics.com. Douglas T Ross. E-mail: dtross@applied-genomics.com 
Abstract
Transplantation of human breast cancer cells into immunodeficient mice together with gene-
expression microarray studies has recently identified genes implicated in the tissue tropism of
breast-cancer metastasis. Such signatures of site-specific metastatic capabilities might allow the
targeting of therapy to likely sites of metastasis.
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Metastases are the primary cause of death of cancer patients,
and improving the means of foretelling their development is
a major goal of current clinical research. Already, new
genomic-based tests predicting the likelihood of tumor
recurrence are making the first tentative steps into the clinic
[1]. Recent work [2-4], most notably studies of breast cancer
by Minn and colleagues [3,4], suggests that it is possible to
refine these tests so that the site of distant recurrence can
also be predicted. Such an enhancement of cancer diagnos-
tics to address the tissue specificity of metastasis would aid
the oncologist and patient by allowing additional treatment
after surgery to be targeted to the tissue. 
The metastatic potential of tumors
The establishment of metastases at sites distant from the
origin of the tumor is non-random, and thus potentially pre-
dictable. Breast tumors, for example, primarily spread to
lung and bone marrow, while colorectal cancer commonly
metastasizes to liver. Some limits to this tumor tropism are
clearly anatomical, relating to the distribution and dimen-
sions of the vascular or lymphatic system that disseminates
circulating tumor cells. As long ago as 1889, however, Paget
[5] suggested the well-known ‘seed and soil’ hypothesis [6],
which proposes that migrating tumor cells (the seeds) are
only able to establish themselves in certain receptive envi-
ronments (the soil). A striking illustration of this intrinsic
specificity of circulating tumor cells was exemplified by a
study of ovarian cancer [7,8], looking at patients with
implanted venous shunts. Ovarian cancer rarely metasta-
sizes outside of the peritoneum, and in this study, although
the shunts allowed vast numbers of ovarian tumor cells to
enter the venous circulation, no increase in distant metasta-
sis was observed [7,8]. Clearly, the cells of a primary tumor
are functionally restricted in terms of the tissues in which
they can establish themselves and proliferate.
How the tissue specificity of metastasis is determined is
unknown, reflecting continued uncertainty about the general
nature of metastatic origins. Several independent lines of
evidence suggest that a tumor is a heterogeneous collection
of cells with varying growth and metastatic potentials (for
reviews see [6,9]). Metastases appear to arise from single
progenitor cells that escape the primary tumor and find
fertile ground for growth elsewhere. Consistent with these
observations, metastasis has long been viewed as a progres-
sive disorder in which the diversity of cells within the tumor
provides a basis for selection of aggressive growth, with the
ultimate escape of a metastatic cell from the primary neo-
plasm and its subsequent establishment in other tissues.
Multi-step tumor progression could imply that a primary
tumor at its earliest stages would, on the whole, provide little
information as to the likelihood or nature of future metasta-
sis. While not invalidating the multi-step model, recentmicroarray-based analyses of the molecular physiology of
tumors at diagnosis and of later occurring metastases
demonstrated that metastases can be very similar molecu-
larly to the primary tumor [10,11]. This suggests that some
aspects of primary tumors, be they genetic or epigenetic, are
stable enough to be inherited by disseminated tumors.
Furthermore, by distinguishing a variety of shared features
within the primary tumors, such microarray studies have
proposed a number of signatures that predict aggressive
disease [1,10,12-16]. These results suggest that the hetero-
geneity of tumors at diagnosis presents phenotypes that
influence their metastatic properties, although they do not
make it clear whether such features represent the product of
mutation and selection or whether they distinguish properties
of the transformed cell type.
Several molecular origins have been proposed for the tissue
tropism of tumor metastases. Compatible adherent molecules
between tumor cell and host tissue, and the presence of
necessary growth factors at the metastatic site, have all been
implicated, and several specific genes have been suggested to
play a role in the distant establishment of a metastasis (for
review see [9]). For example, the chemokine receptor
CXCR4 has been functionally implicated in the lung speci-
ficity of breast tumor metastases, where the tissue-specific
activity of its ligand CXCL12 allows chemokine-mediated
signal activation [17,18]. Similarly, the chemokine receptor
CCR10 found in melanomas has a chemokine ligand CCL27
that is expressed in skin, consistent with the high incidence
of skin metastases [17]. Gene-expression studies that pro-
filed metastases established in mouse models after injection
with human breast or small-cell lung cancer cells have
shown striking differences between the populations of cells
that colonize distinct organs, suggesting that many poten-
tial factors may determine organ-specific metastasis and
modulate the phenotype of tumor cells located at distant
sites [19-21].
Identifying genes governing metastatic tissue
specificity
Recent papers from the Massagué lab [3,4] report exciting
progress in the identification of genes that are functionally
important for tissue-specific metastasis. Of key importance to
the patient and oncologist, this work also provides early indi-
cations that the findings can translate into clinically useful
tools. To assess metastasis, Minn et al. [3] used a model of
breast cancer in which human cancer cells are transplanted
into another species (a xenograft), in this case mice (Figure 1).
Using the human breast carcinoma cell line MDA-MB-231
and microarrays to search for genes expressed in cell lines
that preferentially metastasized to lung as opposed to bone,
they assessed the potential of using these genes in predicting
organ-specific metastasis by injection of cells into
immunodeficient mice. The parental line, when tested as
single cells, displayed heterogeneous metastatic capacities
and tissue tropisms. Serial selection and subcloning allowed
the establishment of human cell lines that efficiently and
preferentially metastasized either to lung or to bone marrow
in immunodeficient mice [3,4].
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Figure 1
Identification of gene-expression signatures associated with organ site-
specific metastasis. The procedure followed by Massagué and colleagues
[3,4] was as follows. (a) Selection of stable lung- and bone-metastatic
sublines of MDA-MB-231 cells in vivo. (b) Comparison of their gene-
expression patterns with parental cell lines. (c) Validation of the role of
signature genes in metastatic activity by confirming that selected genes
when overexpressed or underexpressed alone or in combination altered
the site-specific metastatic activity of the parental line. (d) The lung
signature defined from the above study was predictive of metastatic
activity in an independent clinical cohort of breast cancer patients.
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0.0Gene-expression studies comparing a lung metastatic subline
with the parental line identified 95 genes correlated with lung-
metastatic activity. This gene list was pared down to 54 candi-
date genes by also requiring that these genes be differentially
expressed across multiple independent lung-metastatic
sublines. This gene set was largely distinct from a gene set
that was previously identified in bone metastatic sublines
[4]. Interestingly, the chemokine receptor CXCR4, noted as
a potential effector of lung tropism in other studies, was
among the genes identified in the current investigation [3].
Efforts to validate a subset of nine of the candidate genes
individually through overexpression in the parent cell line
demonstrated little change in lung metastatic activity in
mouse xenograft experiments, with only overexpression of
inhibitor of DNA binding 1 (ID1) showing a small increase in
activity compared to controls. When certain sets of genes
were coexpressed in combinations of three in the parental
line, however, they recapitulated the lung-specific metastatic
activity seen in the original selected cell lines. Bone metasta-
tic activity was not altered by the presence of these con-
structs. Furthermore, knockdown studies performed in a
selected subline revealed that a decrease in the expression of
several genes (ID1, the gene for the cell adhesion molecule
VCAM1, and the IL13R2 gene for the interleukin (IL) 13
receptor) decreased lung metastatic activity tenfold [3].
These functional studies suggest that these genes are not
only markers of lung-specific metastasis, but potential medi-
ators of the process as well.
It has been proposed that for metastases to be established the
effectors necessary for metastasis must probably also provide
a selective benefit at the primary tumor site [22]. Consistent
with this model, injection of the lung metastatic subline into
mouse mammary fat pads showed that, in addition to its
increased lung metastatic activity, it also grew more rapidly
at the primary site compared to the parental line [3]. To
explore the potential role of the individual candidate genes,
Minn  et al. [3] tested stable knockdown lines and found
that decreased expression of ID1 reduced both growth in the
mammary fat pads and lung-metastatic ability. The other
knockdowns tested (SPARC - an extracellular matrix-asso-
ciated protein, VCAM1, and IL13R2) decreased only the
lung-metastatic activity but not primary tumor growth. This
implies that genes involved in metastasis can operate both
through a general increase in primary growth and the
ability to populate specific tissues.
Importantly, this study [3] also explored whether the set of
genes identified in the mouse model system might be able to
distinguish a subclass of breast cancer patients with a ten-
dency to lung metastasis. The association of the expression
of these genes with outcome was measured in a cohort of 82
patients whose lung and bone metastasis-free survival had
been assessed in a 10-year follow-up study. By using gene-
expression microarray data from diagnostic specimens, 12 of
the 54 implicated genes showed a significant association
with lung metastasis-free survival. A lung metastasis classi-
fier defined by these genes and weighted by the univariate
scores was significantly associated with the risk of lung
metastasis, but not with the risk of bone metastases. To
assess the generalization of this model to independent
datasets, Minn et al. [3] derived a new classifier with this set
of genes, training it on an independent breast cancer cohort to
distinguish tumors that shared features with the lung-
metastatic selected subline. When this new classifier was
tested on the original 82-patient cohort, it identified patients
who succumbed to metastasis to lung but not to bone. Minn et
al. [4] had previously shown that a bone-metastasis signature
was similarly able to distinguish patients who suffered bone
metastases from those who suffered lung metastases, although
this signature was not associated with poor outcome.
An understanding of the mechanism of the specificity of
tumor tropism, or at least the ability to predict for an
individual patient their likely site of metastasis, is of more
than academic importance. Lung cancer, for example, fre-
quently metastasizes to the brain and it has been shown that
prophylactic cranial irradiation can be beneficial for patients
with small-cell lung cancer [23]. The potential toxicity of this
therapy has prevented its widespread use, but the ability to
focus the treatment on patients most at risk would be of great
utility. Altogether, the emerging ability to identify tissue-
tropic biomarkers and the maturing of the field of prognosis
predictors promise eventually to allow oncologists to direct
treatment plans to those patients and tissues most at risk. 
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